In postmenopausal women, previous clinical trials of nasal calcitonin have noted rhinitis and epistaxis as the most common adverse effects, with incidence rates of 12% and 4%, respectively.414 Put simply, calcitonin is a relatively less effective antiresorptive therapy for osteoporosis and related fractures, and its benefit does not outweigh the risk of treating osteoporosis.415. The gene discussed is CALCA; the disease is rhinitis.